^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
CART-PSMA- TGFβRDN cells
i
Other names: TmPSMA 01 CAR-T, PSMA-directed/TGFβ-insensitive CAR-T cells, PSMA-specific/TGFβ-resistant CAR modified autologous T cells, CART-PSMA- TGFβRDN cells, TMUN ONC 001, PSMA CAR-T
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Gilead
Drug class:
PSMA-targeted CAR-T immunotherapy, TGF-βRDN-targeted CAR-T immunotherapy
Related drugs:
7ms
CART-PSMA-TGFβRDN Cells for Castrate-Resistant Prostate Cancer (clinicaltrials.gov)
P1, N=23, Active, not recruiting, University of Pennsylvania | Recruiting --> Active, not recruiting
Enrollment closed • Metastases
|
TGFB1 (Transforming Growth Factor Beta 1)
|
FOLH1 expression
|
cyclophosphamide • fludarabine IV • CART-PSMA- TGFβRDN cells
over2years
CART-PSMA-TGFβRDN Cells for Castrate-Resistant Prostate Cancer (clinicaltrials.gov)
P1, N=19, Recruiting, University of Pennsylvania | Active, not recruiting --> Recruiting | Trial completion date: Dec 2022 --> Dec 2038 | Trial primary completion date: Sep 2022 --> Sep 2038
Enrollment open • Trial completion date • Trial primary completion date
|
TGFB1 (Transforming Growth Factor Beta 1)
|
FOLH1 expression
|
cyclophosphamide • fludarabine IV • CART-PSMA- TGFβRDN cells
almost3years
CART-PSMA-TGFβRDN Cells for Castrate-Resistant Prostate Cancer (clinicaltrials.gov)
P1, N=18, Active, not recruiting, University of Pennsylvania | Trial completion date: Sep 2021 --> Dec 2022 | Trial primary completion date: Sep 2021 --> Sep 2022
Clinical • Trial completion date • Trial primary completion date
|
TGFB1 (Transforming Growth Factor Beta 1)
|
FOLH1 expression
|
cyclophosphamide • CART-PSMA- TGFβRDN cells
over3years
A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
P1, N=50, Recruiting, Tmunity Therapeutics | Active, not recruiting --> Recruiting
Clinical • Enrollment open • CAR T-Cell Therapy
|
TGFB1 (Transforming Growth Factor Beta 1)
|
fludarabine IV • CART-PSMA- TGFβRDN cells • Kineret (anakinra) • cyclophosphamide intravenous
almost4years
A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
P1, N=50, Active, not recruiting, Tmunity Therapeutics | Recruiting --> Active, not recruiting
Clinical • Enrollment closed • CAR T-Cell Therapy
|
TGFB1 (Transforming Growth Factor Beta 1)
|
fludarabine IV • CART-PSMA- TGFβRDN cells • Kineret (anakinra) • cyclophosphamide intravenous
over4years
A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
P1, N=50, Recruiting, Tmunity Therapeutics | Active, not recruiting --> Recruiting | N=18 --> 50 | Trial completion date: Apr 2022 --> Nov 2036 | Trial primary completion date: Nov 2020 --> Nov 2022
Clinical • Enrollment open • Enrollment change • Trial completion date • Trial primary completion date • CAR T-Cell Therapy
|
TGFB1 (Transforming Growth Factor Beta 1)
|
fludarabine IV • CART-PSMA- TGFβRDN cells • Kineret (anakinra) • cyclophosphamide intravenous
Share via
